查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2130675

先進影像生物標記市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、最終用戶、功能、安裝類型、模式分類

Advanced Imaging Biomarkers Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Functionality, Installation Type, Mode
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球先進影像生物標記市場預計將從2025年的18億美元成長到2035年的51億美元，複合年成長率（CAGR）為10.7%。隨著診斷影像從定性解讀轉向定量和可重複測量，先進影像生物標記在精準醫療、腫瘤學、神經病學、循環系統和藥物研發等領域的重要性日益凸顯。美國國立衛生研究院（NIH）透過涵蓋癌症、神經系統疾病、心血管疾病和其他疾病的項目，持續支持影像生物標記的研究；與此同時，食品藥物管理局（FDA）正在推進生物標記在藥物研發中的合格評估框架。高場磁振造影（MRI）、正子斷層掃描/電腦斷層掃描（PET/CT）、定量影像分析軟體、放射組學和人工智慧等技術的日益普及，正在推動臨床和研究領域對先進影像生物標記的需求。此外，不斷成長的影像資料集、標準化的成像方案、多中心臨床試驗以及將影像衍生終點整合到精準診斷和治療開發中，也推動了這些技術的應用。

結構生物標記主要利用磁振造影（MRI）、電腦斷層掃描（CT）和高解析度影像技術，量化病灶體積、組織形態、密度和器官結構等解剖學特徵。功能性生物標記則透過功能性磁振造影（fMRI）、正子斷層掃描（PET）和動態影像等技術，評估灌注、代謝、血流、神經活動和組織活力等生理過程。分子生物標記利用分子影像和標靶對比劑，提供有關特定分子路徑、受體、蛋白質和細胞過程的資訊。這些生物標記在疾病表徵、治療監測、患者分層和早期治療反應評估等方面發揮越來越重要的作用。這種成長是由定量成像、人工智慧、多模態整合以及精準醫療和藥物研發領域對非侵入性生物標記的需求所驅動的。

市場區隔
類型 結構生物標記、分子生物標記、功能生物標記及其他
產品 軟體、影像系統、顯影劑及其他
服務 數據分析服務、諮詢服務、安裝服務、維護服務等。
科技 磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）、超音波、X光、單光子發射電腦斷層掃描（SPECT）等
成分 硬體、軟體、服務及其他
目的 腫瘤科、循環系統、神經科、整形外科、胃腸科等。
最終用戶 醫院、診斷中心、研究機構、製藥公司及其他
功能 定量影像診斷、質性影像診斷及其他
發展 新建、升級、改造、其他
模式 侵入性、非侵入性、其他

我們的服務包括專家諮詢、專業培訓、教育、系統維護、技術支援、工作流程最佳化以及影像生物標記實施。我們的諮詢服務協助製藥公司、醫療機構、影像中心和研究機構制定生物標記策略、開發方案、檢驗、確保符合法規要求並整合臨床應用。訓練和教育能夠提升影像擷取、定量分析、結果解讀和生物標記標準化方面的能力。維護和支援服務確保影像平台、軟體、數據管道和分析系統在整個研究和臨床工作流程中的可靠運作。隨著各機構採用先進的影像技術、需要標準化的生物標記工作流程以及尋求外部專家來整合先進的分析和影像基礎設施，市場需求正在不斷成長。

區域概覽

北美憑藉其完善的診斷基礎設施、先進的學術醫療中心、強大的藥物研發能力和成熟的影像技術生態系統，在先進影像生物標記領域中保持著領先地位。 MRI、CT、PET 和混合影像技術在美國的廣泛應用，催生了腫瘤學、神經科學、循環系統和臨床試驗等領域的龐大需求。醫療機構、生物技術公司、影像技術開發商和研究機構之間的合作，正在推動商業化和檢驗活動的發展。聯邦政府的研究經費和支持生物標記開發的監管舉措，進一步鞏固了市場基礎。人工智慧、放射組學、定量成像和多模態生物標記平台的日益普及，正在推動醫療機構和生命科學公司對先進影像技術的應用不斷拓展。

在歐洲，精準醫療、醫學研究基礎設施、數位醫療和先進診斷技術的投資正在推動影像生物標記的應用。德國、英國、法國和瑞士等國都受惠於完善的醫療保健體系、研究機構、製藥公司和專業影像中心。公共資助的研究計畫和歐洲聯合舉措正在加速標準化影像生物標記和可互通資料框架的開發。人工智慧驅動的影像分析和定量成像技術的擴展正在支持腫瘤學、神經系統疾病和臨床研究等領域的應用。製藥和生物技術產業對基於影像的終點指標的投資也在推動市場需求，而對個人化醫療和疾病早期檢測的日益重視則為未來的市場擴張奠定了永續的基礎。

主要趨勢和促進因素

人工智慧影像診斷重新定義了生物標記的準確性：

人工智慧、放射組學和多模態成像技術的融合，正將先進的影像生物標記從主要依賴定性觀察轉變為以數據驅動的定量指標。機器學習演算法能夠提取與疾病特徵、治療反應和患者預後相關的複雜影像特徵，並透過結合磁振造影（MRI）、正子斷層掃描（PET）、電腦斷層掃描（CT）和分子成像技術，提供互補的生物學資訊。這種發展趨勢正不斷提升影像生物標記在精準醫療、臨床試驗、藥物研發和疾病監測等領域的價值。

精準醫療正在加速先進生物標記的應用。

精準醫療需求的日益成長正在加速先進影像生物標記在患者分層、診斷、預後和治療監測中的應用。影像技術能夠以非侵入性方式呈現解剖、生理和分子生物學特徵，使臨床醫生和研究人員無需重複進行侵入性操作即可評估疾病異質性和治療反應。製藥公司也對臨床開發中影像衍生終點表現出越來越濃厚的興趣，從而推動了對檢驗的定量成像方法、標準化方案和先進分析平台的需求。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 結構生物標記
    • 分子生物標記
    • 功能性生物標記
    • 其他
  • 市場規模及預測：依產品分類
    • 軟體
    • 影像系統
    • 顯影劑
    • 其他
  • 市場規模及預測：依服務分類
    • 數據分析服務
    • 諮詢服務
    • 安裝服務
    • 維護服務
    • 其他
  • 市場規模及預測：依技術分類
    • MRI
    • CT
    • PET
    • 超音波
    • X光
    • SPECT
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 循環系統
    • 神經病學
    • 整形外科
    • 胃腸病學
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷中心
    • 研究機構
    • 製藥公司
    • 其他
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
    • 其他
  • 市場規模及預測：依功能分類
    • 定量影像
    • 定性成像
    • 其他
  • 市場規模及預測：依安裝類型分類
    • 新推出
    • 升級
    • 維修
    • 其他
  • 市場規模及預測：按模式
    • 侵入性
    • 非侵入性
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Canon Medical Systems
  • Fujifilm Holdings
  • Hitachi Medical Systems
  • Hologic
  • Agfa-Gevaert
  • Bracco Imaging
  • Carestream Health
  • Esaote
  • Konica Minolta
  • Mindray Medical
  • Samsung Medison
  • Shimadzu Corporation
  • Toshiba Medical Systems
  • Varian Medical Systems
  • PerkinElmer
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories

第9章 關於我們

簡介目錄
Product Code: GIS32777

The global Advanced Imaging Biomarkers Market is projected to grow from $1.8 billion in 2025 to $5.1 billion by 2035, at a compound annual growth rate (CAGR) of 10.7%. Advanced imaging biomarkers are gaining importance within precision medicine, oncology, neurology, cardiology, and pharmaceutical research as imaging shifts from qualitative interpretation toward quantitative, reproducible measurements. The U.S. National Institutes of Health continues to support imaging biomarker research through programs spanning cancer, neurological disorders, cardiovascular disease, and other conditions, while the U.S. Food and Drug Administration promotes biomarker qualification frameworks for drug development. Increasing availability of high-field MRI, PET/CT, quantitative imaging software, radiomics, and artificial intelligence is strengthening clinical and research demand. Adoption is also supported by growing imaging datasets, standardized acquisition protocols, multicenter clinical trials, and the integration of imaging-derived endpoints into precision diagnostics and therapeutic development.

Structural biomarkers quantify anatomical characteristics including lesion volume, tissue morphology, density, and organ architecture, primarily using MRI, CT, and high-resolution imaging. Functional biomarkers evaluate physiological processes such as perfusion, metabolism, blood flow, neural activity, and tissue viability through techniques including functional MRI, PET, and dynamic imaging. Molecular biomarkers provide information on specific molecular pathways, receptors, proteins, and cellular processes using molecular imaging and targeted contrast agents. These categories increasingly support disease characterization, treatment monitoring, patient stratification, and early response assessment. Growth is being supported by quantitative imaging, artificial intelligence, multimodal integration, and demand for non-invasive biomarkers in precision medicine and pharmaceutical development.

Market Segmentation
TypeStructural Biomarkers, Molecular Biomarkers, Functional Biomarkers, Others
ProductSoftware, Imaging Systems, Contrast Agents, Others
ServicesData Analysis Services, Consulting Services, Installation Services, Maintenance Services, Others
TechnologyMRI, CT, PET, Ultrasound, X-ray, SPECT, Others
ComponentHardware, Software, Services, Others
ApplicationOncology, Cardiology, Neurology, Orthopedics, Gastroenterology, Others
End UserHospitals, Diagnostic Centers, Research Institutes, Pharmaceutical Companies, Others
FunctionalityQuantitative Imaging, Qualitative Imaging, Others
Installation TypeNew Installation, Upgrades, Retrofits, Others
ModeInvasive, Non-Invasive, Others

Services encompass specialized consulting, professional training, education, system maintenance, technical support, workflow optimization, and imaging-biomarker implementation. Consulting services assist pharmaceutical companies, healthcare organizations, imaging centers, and research institutions with biomarker strategy, protocol development, validation, regulatory alignment, and clinical integration. Training and education improve competency in image acquisition, quantitative analysis, interpretation, and biomarker standardization. Maintenance and support services ensure imaging platforms, software, data pipelines, and analytical systems operate reliably throughout research and clinical workflows. Demand is expanding as organizations adopt sophisticated imaging technologies, require standardized biomarker workflows, and seek external expertise for integrating advanced analytics and imaging infrastructure.

Geographical Overview

North America maintains a strong position in advanced imaging biomarkers through extensive diagnostic infrastructure, sophisticated academic medical centers, pharmaceutical research capabilities, and established imaging technology ecosystems. The United States provides a substantial demand base through oncology, neuroscience, cardiology, and clinical-trial applications, supported by widespread MRI, CT, PET, and hybrid imaging capabilities. Collaboration among healthcare providers, biotechnology companies, imaging technology developers, and research institutions strengthens commercialization and validation activities. Federal research funding and regulatory initiatives supporting biomarker development further reinforce market infrastructure. Increasing adoption of artificial intelligence, radiomics, quantitative imaging, and multimodal biomarker platforms is encouraging healthcare organizations and life-sciences companies to expand advanced imaging applications.

Europe is experiencing broader adoption of imaging biomarkers through investments in precision medicine, medical research infrastructure, digital health, and advanced diagnostic technologies. Countries including Germany, the United Kingdom, France, and Switzerland benefit from established healthcare systems, research institutions, pharmaceutical companies, and specialized imaging centers. Publicly funded research programs and European collaborative initiatives are encouraging development of standardized imaging biomarkers and interoperable data frameworks. Expansion of AI-enabled image analysis and quantitative imaging is supporting applications in oncology, neurological disorders, and clinical research. Pharmaceutical and biotechnology investments in imaging-based endpoints are also strengthening demand, while increasing emphasis on personalized healthcare and earlier disease detection provides a sustained foundation for future market expansion.

Key Trends and Drivers

AI-Powered Imaging Redefining Biomarker Precision:

Integration of artificial intelligence, radiomics, and multimodal imaging is transforming advanced imaging biomarkers from primarily qualitative observations into quantitative, data-driven indicators. Machine learning algorithms can extract complex imaging features associated with disease characteristics, treatment response, and patient outcomes, while combining MRI, PET, CT, and molecular imaging can provide complementary biological information. This evolution is increasing the value of imaging biomarkers in precision medicine, clinical trials, drug development, and longitudinal disease monitoring.

Precision Medicine Accelerating Advanced Biomarker Adoption:

Growing demand for precision medicine is accelerating the use of advanced imaging biomarkers for patient stratification, diagnosis, prognosis, and treatment monitoring. Imaging provides non-invasive access to anatomical, physiological, and molecular characteristics, enabling clinicians and researchers to evaluate disease heterogeneity and therapeutic response without repeated invasive procedures. Pharmaceutical companies are also increasing interest in imaging-derived endpoints for clinical development, strengthening demand for validated quantitative imaging methods, standardized protocols, and advanced analytical platforms.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Installation Type
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Structural Biomarkers
    • 4.1.2 Molecular Biomarkers
    • 4.1.3 Functional Biomarkers
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Imaging Systems
    • 4.2.3 Contrast Agents
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Data Analysis Services
    • 4.3.2 Consulting Services
    • 4.3.3 Installation Services
    • 4.3.4 Maintenance Services
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 MRI
    • 4.4.2 CT
    • 4.4.3 PET
    • 4.4.4 Ultrasound
    • 4.4.5 X-ray
    • 4.4.6 SPECT
    • 4.4.7 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Orthopedics
    • 4.5.5 Gastroenterology
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Centers
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Services
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Quantitative Imaging
    • 4.8.2 Qualitative Imaging
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Installation Type (2020-2035)
    • 4.9.1 New Installation
    • 4.9.2 Upgrades
    • 4.9.3 Retrofits
    • 4.9.4 Others
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Invasive
    • 4.10.2 Non-Invasive
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Functionality
      • 5.2.1.9 Installation Type
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Functionality
      • 5.2.2.9 Installation Type
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Functionality
      • 5.2.3.9 Installation Type
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Functionality
      • 5.3.1.9 Installation Type
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Functionality
      • 5.3.2.9 Installation Type
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Functionality
      • 5.3.3.9 Installation Type
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Functionality
      • 5.4.1.9 Installation Type
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Functionality
      • 5.4.2.9 Installation Type
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Functionality
      • 5.4.3.9 Installation Type
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Functionality
      • 5.4.4.9 Installation Type
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Functionality
      • 5.4.5.9 Installation Type
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Functionality
      • 5.4.6.9 Installation Type
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Functionality
      • 5.4.7.9 Installation Type
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Functionality
      • 5.5.1.9 Installation Type
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Functionality
      • 5.5.2.9 Installation Type
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Functionality
      • 5.5.3.9 Installation Type
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Functionality
      • 5.5.4.9 Installation Type
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Functionality
      • 5.5.5.9 Installation Type
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Functionality
      • 5.5.6.9 Installation Type
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Functionality
      • 5.6.1.9 Installation Type
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Functionality
      • 5.6.2.9 Installation Type
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Functionality
      • 5.6.3.9 Installation Type
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Functionality
      • 5.6.4.9 Installation Type
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Functionality
      • 5.6.5.9 Installation Type
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 GE Healthcare
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Siemens Healthineers
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Philips Healthcare
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Canon Medical Systems
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fujifilm Holdings
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Hitachi Medical Systems
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Hologic
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Agfa-Gevaert
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bracco Imaging
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Carestream Health
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Esaote
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Konica Minolta
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Mindray Medical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Samsung Medison
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Shimadzu Corporation
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Toshiba Medical Systems
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Varian Medical Systems
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 PerkinElmer
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Thermo Fisher Scientific
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bio-Rad Laboratories
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us